Last reviewed · How we verify
SKYRIZI
SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.
SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23. Used for Moderate to severe plaque psoriasis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | SKYRIZI |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | IL-23 inhibitor monoclonal antibody |
| Target | IL-23 (p19 subunit) |
| Modality | Biologic |
| Therapeutic area | Immunology/Dermatology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting IL-23, risankizumab reduces the differentiation and activation of pathogenic T cells (particularly Th17 cells) that drive inflammatory responses in the skin and immune system. This targeted approach to the IL-23 pathway helps suppress the chronic inflammation characteristic of psoriasis and other inflammatory conditions without broadly suppressing the entire immune system.
Approved indications
- Moderate to severe plaque psoriasis
- Crohn's disease
- Ulcerative colitis
Common side effects
- Upper respiratory tract infection
- Injection site reactions
- Headache
- Fatigue
Key clinical trials
- A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease (PHASE3)
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (PHASE4)
- Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
- A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease (PHASE4)
- Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis (PHASE4)
- A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab (PHASE3)
- An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
- Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SKYRIZI CI brief — competitive landscape report
- SKYRIZI updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI